key: cord-0909539-7hjlcri1 authors: Adlam, David; Chan, Nathan; Baron, Julia; Kovac, Jan title: Aortic stenosis in the time of COVID‐19: Development and outcomes of a rapid turnaround TAVI service date: 2021-02-10 journal: Catheter Cardiovasc Interv DOI: 10.1002/ccd.29550 sha: 5fc87268b068b35abd004bf83e7267b3ae387ec9 doc_id: 909539 cord_uid: 7hjlcri1 The COVID‐19 pandemic has resulted in the cancellation of many elective surgical procedures. This has led to reports of an increase in mortality for patients with non‐Covid health conditions due to delayed definitive management. Patients with severe aortic stenosis have a high annual mortality if left untreated. These patients are at risk due to the reduced number of surgical aortic valve replacements and competition for intensive care facilities during the COVID‐19 pandemic. This case series suggests that the minimally invasive transcatheter aortic valve implantation is safe to continue during the COVID‐19 pandemic with adjustments to the patient pathway to minimize hospital stay and to reduce patient and staff exposure. This helps to reduce the delay of definitive treatment for patients with severe aortic stenosis. Symptomatic severe aortic stenosis (AS) managed medically carries an annual mortality of approximately 50%. 1 TAVI has become a wellestablished treatment for severe aortic stenosis in patients with a high surgical risk 2,3 and is increasingly considered across a spectrum of more moderate surgical risks. 4 The current pandemic of the highly infectious coronavirus COVID-19 has posed significant challenges to health care systems internationally. COVID-19 is associated with a high incidence of primary respiratory failure requiring invasive mechanical ventilation, putting increased pressure on intensive care units (ITU) . 5 This has led to the cancellation of a huge number of elective operations. 6 In particular, most cardiac centres have had to suspend or significantly reduce their elective cardiothoracic surgery services including surgical AVR. 5 However, a significant proportion of the increased population mortality during the COVID-19 pandemic is not directly attributable to the virus itself. Delayed presentation and deferred definitive management of non-Covid health conditions are likely to account for much of this excess mortality. 6, 7 Due to the dire prognosis of untreated severe stenosis, our cardiac centre made the decision to continue TAVI procedures throughout the COVID-19 pandemic to date but with adjustments to the process aimed at rapid patient discharge, minimizing hospital stay, reducing potential staff and patient exposure and avoiding use of ITU and theater (including hybrid) facilities ( Figure 1 ). The following changes were made: (Table 1) . Patient characteristics and outcomes including procedural mortality and complications are shown in Table 2 . Patient baseline characteristics were similar in both groups. The median Euroscore II for the COVID-19 group was 3.03% compared to 4.05% in the pre COVID-19 group but was not a significant difference. Three (7.5%) patients in the COVID-19 group required a valve-in-valve procedure compared to no patients in the pre COVID-19 group. An increase in Edwards There were no procedural deaths in both groups of patients. Complication rates were similar in both groups, with both having 6 (15%) patients requiring pacemaker implantations following their procedure and both having 1 (2.5%) patient with a major vascular complication. 4 (10%) patients required blood transfusions in the pre COVID-19 group compared to none in the COVID-19 group. One patient in the COVID-19 group suffered from a periprocedural myocardial infarction whilst none did in the pre COVID-19 group. No patients in the COVID-19 group required blood transfusions due to post procedural bleeding compared to 4 (10%) who did in the pre COVID-19 group. Only 1 (2.5%) patient had moderate or worse Aortic Regurgitation (AR) after deployment of the new valve in the COVID-19 group compared to 3 (7.5%) in the pre COVID-19 group. The length of stay in hospital is shown in Figure 2 , more patients were discharged on day 1 or 2 in the COVID-19 group. All patients were discharged home. There were no patients with mortality at 30-days in the COVID-19 group, however there were two patients with a 30-day mortality in the pre COVID-19 group. The first patient had an annular rupture during his TAVI procedure leading to cardiac tamponade. Although pericardiocentesis was successful, he continued to deteriorate and was started on palliative management. The second death was a patient who developed bowel ischaemia 5 days post procedure. After discharge there were 5 (12.5%) patients in both groups that required a hospital readmission after discharge. In the COVID-19 group, 1 patient was readmitted for vascular complications, 1 for decompensated heart failure, 2 with chest infections and 1 for musculoskeletal chest pain. All repeat COVID-19 swabs were negative. In the pre COVID-19 group, 1 patient was readmitted for decompensated heart failure, 2 for transient limb weakness felt due to transient ischaemic attacks (TIAs), 1 for delirium due to pneumonia and 1 for shortness of breath. In the COVID-19 group, all patients were remotely followed up There is some potential for selection bias with lower risk patients potentially selected for procedures during the pandemic, although the patient's baseline characteristics before and after lockdown are similar. During the initial period of the lockdown, patients in the preexisting list were prioritized based on clinical need. A small proportion of patients chose to reject or postpone an offered date for TAVI due to concern about the in-hospital COVID-19 infection risk. Importantly, only one patient out of the 40 tested positive for COVID-19 and this patient was known to be positive prior to the procedure, which was conducted after detailed MDT discussion to aid recovery. None of the patients that underwent a TAVI procedure during COVID-19 required ICU admission. Adoption of a fully local anesthetic, transfemoral, catheter laboratory-based practice with mandatory arterial device closure and early pacing (where indicated) were key to avoiding an ITU requirement and ensuring rapid discharge. The current COVID-19 pandemic is a defining event that will shape the healthcare system worldwide for some time to come. With such a heavy focus on COVID-19, it is paramount not to forget the numerous "excess deaths" not directly attributable to COVID-19, inadvertently caused by delayed presentation and diagnosis of patients and the increased burden on healthcare systems. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial Transcatheter versus surgical aortic-valve replacement in high-risk patients 2-Year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients Adult cardiac surgery during the COVID-19 pandemic: a tiered patient triage guidance statement What is happening to non-Covid deaths? Office of National Statistics. Analysis of death registrations not involving coronavirus (COVID-19) Aortic stenosis in the time of COVID-19: Development and outcomes of a rapid turnaround TAVI service This case series is suggestive that with the proper precautions, cardiac centres can continue to perform TAVI safely with good outcomes and minimal burden on stretched inpatient and ITU services. The authors declare no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.